Aclaris Therapeutics Inc
NASDAQ:ACRS

Watchlist Manager
Aclaris Therapeutics Inc Logo
Aclaris Therapeutics Inc
NASDAQ:ACRS
Watchlist
Price: 3.52 USD 2.62% Market Closed
Market Cap: $381.4m

Net Margin

-900%
Current
Declining
by 444.3%
vs 3-y average of -455.7%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-900%
=
Net Income
$-141.7m
/
Revenue
$15.7m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-900%
=
Net Income
$-141.7m
/
Revenue
$15.7m

Peer Comparison

Country Company Market Cap Net
Margin
US
Aclaris Therapeutics Inc
NASDAQ:ACRS
381.4m USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
978.7B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
547.3B USD
Loading...
CH
Roche Holding AG
SIX:ROG
277.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210B GBP
Loading...
CH
Novartis AG
SIX:NOVN
220.8B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
273B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
150.2B USD
Loading...
FR
Sanofi SA
PAR:SAN
95.7B EUR
Loading...

Market Distribution

Lower than 93% of companies in the United States of America
Percentile
7th
Based on 15 072 companies
7th percentile
-900%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Aclaris Therapeutics Inc
Glance View

Market Cap
381.4m USD
Industry
Pharmaceuticals

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. The company is headquartered in Wayne, Pennsylvania and currently employs 75 full-time employees. The company went IPO on 2015-10-07. The firm is focused on leveraging its experience in drug discovery and development and kinase inhibition to develop small molecule therapies to help people impacted immuno-inflammatory conditions. The Company’s drug candidates are Zunsemetinib (ATI-450), ATI-1777 and ATI-2138. The Company’s ATI-450, an investigational oral, small molecule selective MK2 inhibitor compound, for the treatment of rheumatoid arthritis. Its ATI-1777, an investigational topical soft-JAK 1/3 inhibitor compound, for the treatment of atopic dermatitis. The firm is engaged in developing ATI-2138, its investigational oral inhibitor compound, as a potential treatment for T-cell mediated autoimmune diseases. The company is also developing oral gut biased JAK inhibitors, as a potential treatment for inflammatory bowel disease.

ACRS Intrinsic Value
0.25 USD
Overvaluation 93%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-900%
=
Net Income
$-141.7m
/
Revenue
$15.7m
What is Aclaris Therapeutics Inc's current Net Margin?

The current Net Margin for Aclaris Therapeutics Inc is -900%, which is below its 3-year median of -455.7%.

How has Net Margin changed over time?

Over the last 3 years, Aclaris Therapeutics Inc’s Net Margin has decreased from -349.2% to -900%. During this period, it reached a low of -900% on Sep 30, 2025 and a high of -136.6% on Sep 30, 2024.

Back to Top